The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.
For PDF sample Copy or More Details please visit link @: https://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market
High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.
A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.
Further key findings from the report suggest:
• Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
• Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
• Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
• Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
• Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
• Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
• Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
• Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
• Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.
To request research report sample copy with TOC please visit @: https://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market/request/rs1
Grand View Research has segmented the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market on the basis of PGD/PGS, type, application, and region:
Preimplantation Genetic Testing (PGT) PGD/PGS Outlook (Revenue, USD Million, 2014 - 2024)
• Preimplantation Genetic Diagnosis (PGD)
• Preimplantation Genetic Screening (PGS)
Preimplantation Genetic Testing (PGT) (PGS/PGD) Type Outlook (Revenue, USD Million, 2014 - 2024)
• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
o Fresh Embryo (Own Eggs)
o Frozen Embryo (Own Eggs)
o Fresh Embryo (Donor Eggs)
o Frozen Embryo (Donor Eggs)
• Aneuploidy Screening
• HLA Typing
• Other PGT Types
Preimplantation Genetic Testing (PGT) (PGS/PGD) Application Outlook (Revenue, USD Million, 2014 - 2024)
• Embryo HLA typing for stem cell therapy
• IVF Prognosis
• Late Onset Genetic Disorders
• Inherited Genetic Disease
• Others
Preimplantation Genetic Testing (PGT) (PGS/PGD) Regional Outlook (Revenue, USD Million, 2014 - 2024)
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o Spain
o Belgium
o Czech Republic
o Poland
o Sweden
o Finland
o Norway
o Netherlands
o Italy
• Asia Pacific
o Japan
o China
o India
o Singapore
o Malaysia
• Latin America
o Brazil
o Mexico
o Argentina
o Chile
• Middle East and Africa (MEA)
o South Africa
For Inquire before buying please visit @: https://www.grandviewresearch.com/inquiry/3258/ibb
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.